Back to Search Start Over

Prognostic impact of a ground glass opacity component in the clinical T classification of non-small cell lung cancer.

Authors :
Hattori A
Matsunaga T
Takamochi K
Oh S
Suzuki K
Source :
The Journal of thoracic and cardiovascular surgery [J Thorac Cardiovasc Surg] 2017 Dec; Vol. 154 (6), pp. 2102-2110.e1. Date of Electronic Publication: 2017 Sep 01.
Publication Year :
2017

Abstract

Objective: To determine whether solid component size and the presence of a ground glass opacity (GGO) component are independently associated with survival outcomes in patients with early-stage non-small cell lung cancer (NSCLC) using the eighth edition Lung Cancer Stage Classification.<br />Methods: We retrospectively evaluated 1029 surgically resected early-stage NSCLCs. T categories were assigned based on solid component size using the eighth classification. All tumors were classified into 1 of 2 groups: the GGO group or the solid group. We evaluated the prognostic impact of several clinicopathological variables in clinical T classification using a Cox proportional hazard model.<br />Results: On multivariable analysis, the presence of a GGO component (hazard ratio [HR], 0.314; 95% confidence interval [CI], 0.181-0.529: P < .001) and solid component size (HR, 1.021; 95% CI, 1.006-1.036; P = .006) were identified as independently significant prognostic factors of overall survival. However, after accounting for the presence of a GGO component, neither maximum tumor size nor solid component size added to the prediction of long-term survival. Moreover, tumor size significantly affected survival outcome only in the solid group (HR, 1.020; 95% CI, 1.006-1.034; P = .004). Survival was excellent at ≥90% despite the revised T categories, provided that the tumor had a ground glass appearance. Meanwhile, tumor size significantly affected survival only in the solid group (P < .001).<br />Conclusions: The presence of a GGO component is a significant prognostic factor in early-stage NSCLC. External validation is required to assess whether it should be adopted as a novel factor in clinical T staging.<br /> (Copyright © 2017 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1097-685X
Volume :
154
Issue :
6
Database :
MEDLINE
Journal :
The Journal of thoracic and cardiovascular surgery
Publication Type :
Academic Journal
Accession number :
28947198
Full Text :
https://doi.org/10.1016/j.jtcvs.2017.08.037